|
Market Closed -
Nasdaq
16:00:00 2026-10-30 EDT
|
5-day change | 1st Jan Change | ||
| 27.55 USD | -4.41% |
|
+16.99% | +33.74% |
| 10-27 | Neurogene Inc. Presents New Data On NGN-401 Gene Therapy For Rett Syndrome | CI |
| 10-08 | JPMorgan Initiates Neurogene at Overweight With $60 Price Target | MT |
| Market Cap | 551M 494M 454M 412M 769M 52.35B 784M 5.42B 2.17B 27.54B 2.07B 2.03B 86.84B | P/E 2026 * |
-4.75x | P/E 2027 * | -4.81x |
|---|---|---|---|---|---|
| Enterprise Value | 253M 226M 208M 189M 353M 24B 359M 2.48B 997M 12.63B 949M 929M 39.82B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
93.02% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| NGNE | Delayed | |
CBOE
| NGNE | Real-time | |
|
Tradegate
| UU8 | Real-time | |
|
Börse Stuttgart
| UU8 | Delayed | |
|
Deutsche Boerse AG
| UU8 | Delayed |
Last Transcript: Neurogene Inc.
| 1 day | -4.41% | ||
| 1 week | +16.99% | ||
| 1 month | -0.97% | ||
| 3 months | -16.24% | ||
| 6 months | +5.60% | ||
| Current year | +33.74% |
| 1 week | 23.26 |  | 32.09 |
| 1 month | 21.05 | | 32.09 |
| Current year | 15.93 | | 43.66 |
| 1 year | 15.93 | | 43.66 |
| 3 years | 6.88 | | 74.49 |
| 5 years | 6.88 | | 74.49 |
| 10 years | 6.88 | | 74.49 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/22/26 | Exercice | Chief Executive Officer | 1,512 | 0.0076% | ||
| 7/7/26 | Sell | Chairperson | -4,200 | 0.0270% | ||
| 7/2/26 | Sell | Chairperson | -4,061 | 0.0261% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.41% | +16.99% | -19.59% | - | 551M | |
| -0.62% | -1.87% | +42.87% | +64.15% | 63.77B | |
| +0.35% | +3.20% | +14.40% | +81.76% | 56.37B | |
| +0.53% | +1.96% | +16.24% | +103.35% | 54.62B | |
| -2.81% | -4.31% | +23.50% | +47.83% | 44.06B | |
| -0.33% | -1.93% | +19.28% | +98.80% | 42.11B | |
| +0.55% | +2.31% | +225.14% | +866.21% | 41B | |
| +3.27% | +47.96% | +112.84% | +96.58% | 34.92B | |
| +1.22% | -1.44% | +14.57% | +46.95% | 32.82B | |
| +0.89% | +20.55% | -40.62% | +349.24% | 24.7B | |
| Average | -0.14% | +8.48% | +40.86% | +194.99% | 39.49B | |
| Weighted average by Cap. | +0.17% | +5.46% | +47.90% | +176.67% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -137M -123M -113M -102M -191M -12.99B -194M -1.34B -540M -6.83B -513M -503M -21.55B | -153M -137M -126M -114M -213M -14.5B -217M -1.5B -602M -7.63B -573M -561M -24.05B |
| Net Debt | -298M -267M -246M -223M -416M -28.34B -424M -2.93B -1.18B -14.91B -1.12B -1.1B -47.02B | -180M -161M -149M -135M -252M -17.12B -256M -1.77B -711M -9.01B -677M -662M -28.4B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-30 | US$27.55 | -4.41% | 249,047 |
| 26-10-29 | US$28.82 | -5.26% | 309,996 |
| 26-10-28 | US$30.42 | +12.71% | 646,310 |
| 26-10-27 | US$26.99 | +14.66% | 484,953 |
| 26-10-26 | US$23.54 | -0.04% | 123,203 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NGNE Stock
Select your edition
All financial news and data tailored to specific country editions
